Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus

We have evaluated the efficacy of dapagliflozin in patients with type 1 diabetes mellitus (DM1) without adequate control. We expected that adding dapagliflozin to this population on top of their base treatment would lower their HbA1c levels. We conducted a pragmatic, open, 24-week study of treatment with 10 mg of oral dapagliflozin in patients with DM1 and chronic hyperglycemia. We evaluated glycemic control, lipid profile, weight, and insulin dose. Safety was assessed by adverse event reporting. Fasting glucose levels decreased from 176.42 ± 45.33 mg/dL to 139.67 ± 44.42 mg/dL (p = 0.05); although no significant valued was reached, postprandial glucose showed a decreased tendency from 230.25 ± 52.06 mg/dL to 193.83 ± 45.43 mg/dL ( p = 0.08). The hemoglobin A1C (HbA1C) level decreased from 9.18 ± 1.02 (77 ± 11.1 mmol/mol) to 8.05 ± 1.09 % (64 ± 11.9 mmol/mol) ( p = 0.0156); total cholesterol decreased from 299 ± 12 to 199 ± 7 mg/dL ( p = 0.02); triglycerides decreased from 184 ± 15 to 160 ± 11 mg/dL ( p = 0.0002), HDL-C decreased from 40 ± 17 to 42 ± 9 mg/dL ( p = 0.54); and LDL-C decreased from 187 ± 19 to 170 ± 21 mg/dL ( p = 0.049). No adverse events were reported. The beneficial effects of SGLT2 inhibitors on metabolic control and their safety after a 24-week open study demonstrate their potential indication as an adjunctive treatment with insulin in patients with DM1; however, long-term clinical trials should be considered.